Kidney international · 2026
Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yezhou, Lyu Yizhen, Liu Yamei, Zhang Jiaheng, Song Zhaojie, Chen Kangyu, Jiang Zhixin, Yan Hong, Chen Tao, Li Chao
Аннотация
INTRODUCTION: Despite established cardiovascular benefits, the effects of intensive blood pressure (BP) lowering and specific agents on kidney function remain debated. Here, we assessed these effects using a validated hierarchical composite kidney endpoint (HCE) that prioritizes clinical severity.
METHODS: This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m2, eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties.
RESULTS: A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58-0.64]) and ACCORD-BP (WO, 0.64 [0.59-0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84-0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25-1.33]) and amlodipine (WO, 1.38 [1.34-1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93-0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses.
CONCLUSIONS: Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation.
TRIAL REGISTRATION: Registered at Clinicaltrials.gov with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.
METHODS: This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m2, eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties.
RESULTS: A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58-0.64]) and ACCORD-BP (WO, 0.64 [0.59-0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84-0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25-1.33]) and amlodipine (WO, 1.38 [1.34-1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93-0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses.
CONCLUSIONS: Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation.
TRIAL REGISTRATION: Registered at Clinicaltrials.gov with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.